| 2026-08-06 | Press release | BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease |
| 2026-06-02 | Presentation | Download PDF file, (opens in new window) |
| 2026-06-02 | Press release | Download , Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2, May 27, 2026, (opens in new wind |
| 2026-05-26 | Press release | Download , BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symp |
| 2026-05-26 | Press release | BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associ |
| 2026-05-18 | Press release | Download , BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease, May 18, 2026, (op |
| 2026-05-18 | Press release | BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease |
| 2026-04-27 | Press release | Download , BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's |
| 2026-04-14 | Press release | BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting |
| 2026-04-01 | Presentation | Download PDF (opens in new window) |
| 2026-03-12 | Press release | Download , BioVie Announces Abstract Accepted for Presentation at AD/PD 2026, March 12, 2026, (opens in new window) |
| 2026-03-12 | Press release | BioVie Announces Abstract Accepted for Presentation at AD/PD 2026 |
| 2026-02-23 | Press release | Download , Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4, February 23, 2026, (opens in new wi |
| 2026-02-12 | Press release | Download , BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Mee |
| 2026-02-12 | Press release | BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting |
| 2026-01-10 | Presentation | Download PDF (opens in new window) |
| 2026-01-08 | Press release | Download , BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease, January 8, 2026, (opens |
| 2026-01-08 | Press release | BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease |
| 2025-11-19 | Press release | Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9 |
| 2025-09-26 | Press release | BioVie to Host Live Investor Webinar and Q&A on Oct. 8 |
| 2025-08-13 | Press release | BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Lo |
| 2025-08-11 | Press release | BioVie Inc. Announces Closing of $12 Million Public Offering |
| 2025-08-07 | Press release | BioVie Inc. Announces Pricing of $12 Million Public Offering |
| 2025-07-24 | Press release | BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Adv |
| 2025-07-22 | Press release | BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors |
| 2025-07-09 | Press release | BioVie Announces Data Highlighting Bezisterim’s Potential to Slow or Reverse Biological Aging and Neurodegeneration Feat |
| 2025-06-26 | Press release | BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® C |
| 2025-06-24 | Press release | BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Con |
| 2025-05-15 | Press release | BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the |
| 2025-05-14 | Press release | BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on |
| 2025-05-07 | Press release | BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Di |
| 2025-05-05 | Press release | BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and |
| 2025-04-16 | Press release | BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled |
| 2025-03-27 | Press release | BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, |
| 2025-03-18 | Fact sheet | Download |
| 2024-11-20 | Press release | BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long |
| 2024-11-04 | Press release | BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded |
| 2024-10-29 | Press release | BioVie Inc. Announces Closing of Registered Direct Offering |
| 2024-10-28 | Press release | UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules |
| 2024-10-28 | Press release | BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules |